拉蒂戈生物治疗

最新新闻

• Goldman Sachs Initiates Latigo Biotherapeutics(LTGO.US) With Buy Rating, Announces Target Price $73
  \u5e02\u573a\u8d44\u8baf · 2026/9/1
• Goldman Sachs Maintains Latigo Biotherapeutics(LTGO.US) With Buy Rating, Maintains Target Price $73
  \u5e02\u573a\u8d44\u8baf · 2026/9/4
• Guggenheim Initiates Latigo Biotherapeutics(LTGO.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• Jefferies Initiates Latigo Biotherapeutics(LTGO.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• Analysts Offer Insights on NA Companies: Latigo Biotherapeutics, Inc. (LTGO), Golar LNG (GLNG) and Mobility Global Inc (MBGL)
  TipRanks · 2026/9/2

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。